超声导管介导微泡加速低剂量溶栓治疗外周动脉闭塞的可行性
本研究在体外血管模型和猪外周动脉闭塞模型中评估经超声导管动脉内输注微泡( SonoVue 与 Luminity )辅助低剂量尿激酶溶栓的可行性与溶栓效果。超声暴露使 SonoVue 和 Luminity 微泡存活率分别降低 37% 和 62%;体外 CEST 组 D-二聚体中位数高于单纯溶栓组;猪模型显示动脉血流中位数改善 21%,并观察到 1 例过敏反应和 2 例心律失常。
要点
- 超声暴露使 SonoVue 和 Luminity 微泡存活率分别降低 37% 和 62%(均 p=0.000)。
- 体外 CEST 中 SonoVue 组和 Luminity 组 D-二聚体中位数均高于单纯溶栓组。
- 猪模型 CEST 后动脉血流中位数改善 21%(7%-79%),观察到 1 例过敏反应和 2 例心律失常。
核心结论
- SonoVue 和 Luminity 微泡可与超声导管联合使用,可能加速外周动脉闭塞的溶栓治疗。
研究设计与样本
- 体外研究:SonoVue 和 Luminity 微泡以 20 mL/h 流速经超声导管药物输送腔(DDC,n=20)或血管模型管腔(系统性输注,n=20)输注,联合低剂量尿激酶方案(50 000 IU/h)伴或不伴超声,评估微泡存活率和大小。
- 体外溶栓效果:人血栓置于流动系统血管模型中,比较 5 种处理条件(生理盐水、尿激酶、尿激酶+超声、尿激酶+超声+SonoVue、尿激酶+超声+Luminity)后 D-二聚体浓度。
- 体内研究:5 只猪模型评估局部微泡和超声输送的溶栓效果,指标包括动脉血流、微循环及死后血栓重量和剩余长度。
主要发现
- 超声暴露使 SonoVue 存活率降低 37%(p=0.000),Luminity 存活率降低 62%(p=0.000)。
- 体外 CEST 后 SonoVue 组 D-二聚体中位数为 0.94(0.07-7.59)mg/mL(p=0.025),Luminity 组为 0.83(0.09-2.53)mg/mL(p=0.048),均高于单纯溶栓组的 0.36(0.02-1.00)mg/mL。
- 猪模型 CEST 后动脉血流中位数改善 21%(7%-79%),血栓重量中位数 1.02(0.96-1.43)g,剩余长度中位数 2.25(1.5-4.0)cm。
- 猪模型观察到 1 例过敏反应和 2 例心律失常,归因于对脂质的已知过敏反应。
临床怎么用
- 作者认为 SonoVue 和 Luminity 可与超声导管联合使用,可能加速外周动脉闭塞的溶栓治疗。
局限性
- 猪模型观察到 1 例过敏反应和 2 例心律失常,为对脂质的已知过敏反应所致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intra-arterial administration of microbubbles (MBs) through an ultrasound (US) catheter increases the local concentration of MBs into the thrombus and may further enhance outcomes of contrast-enhanced sonothrombolysis (CEST). The objective of this study was to evaluate the feasibility and lytic efficacy of intra-arterial infusion of MBs during US-enhanced thrombolysis in both in vitro and in vivo peripheral arterial occluded models. MATERIALS AND METHODS: SonoVue and Luminity MBs were infused at a flow rate of 20 mL/h through either the drug delivery lumen of the US catheter (DDC, n=20) or through the tube lumen of the vascular phantom (systematic infusion, n=20) during thrombolysis with a low-dose urokinase (UK) protocol (50 000 IU/h) with(out) US application to assess MB survivability and size by pre-treatment and post-treatment measurements. A human thrombus was placed into a vascular phantom of the flow system to examine the lytic effects of CEST by post-treatment D-dimer concentrations measurements of 5 treatment conditions (saline, UK, UK+US, UK+US+SonoVue, and UK+US+Luminity). Thrombolytic efficacy of localized MBs and US delivery was then investigated in vivo in 5 porcine models by arterial blood flow, microcirculation, and postmortem determined thrombus weight and remaining length. RESULTS: US exposure significantly decreased SonoVue (p=0.000) and Luminity (p=0.000) survivability by 37% and 62%, respectively. In vitro CEST treatment resulted in higher median D-dimer concentrations for the SonoVue (0.94 [0.07-7.59] mg/mL, p=0.025) and Luminity (0.83 [0.09-2.53] mg/mL, p=0.048) subgroups when compared with thrombolysis alone (0.36 [0.02-1.00] mg/mL). The lytic efficacy of CEST examined in the porcine model showed an improved median arterial blood flow of 21% (7%-79%), and a median thrombus weight and length of 1.02 (0.96-1.43) g and 2.25 (1.5-4.0) cm, respectively. One allergic reaction and 2 arrhythmias were observed due to the known allergic reaction on lipids in the porcine model. CONCLUSION: SonoVue and Luminity can be combined with an US catheter and could potentially accelerate thrombolytic treatment of peripheral arterial occlusions. CLINICAL IMPACT: Catheter-directed thrombolysis showed to be an effective alternative to surgery for acute peripheral arterial occlusions, but this technique is still associated with several limb and life-threatening complications. The effects of thrombolysis on clot dissolution may be further enhanced by intra-arterial administration of microbubbles through an ultrasound catheter. This study demonstrates the feasibility and lytic efficacy of intra-arterial infusion of microbubbles during US-enhanced thrombolysis in both in vitro and in vivo peripheral arterial occluded models.
引用
- Doelare SAN, Nederhoed JH, Evers JM, et al. Feasibility of Microbubble-Accelerated Low-Dose Thrombolysis of Peripheral Arterial Occlusions Using an Ultrasound Catheter. J Endovasc Ther. 2022. PMID: 36172738. doi:10.1177/15266028221126938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。